MitoQ for leg pain when walking caused by peripheral artery disease
Tests MitoQ in people with peripheral artery disease who have leg pain walking.
Key facts
- Who runs it
- University of Nebraska
- Where
- Omaha, United StatesSee the site
- Trial code
- Registry title
- MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 1 Jun 2023
- Expected to end
- Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Walking assessment
- QOL Survey
- Ankle pressure at rest and after stress
- Muscle Oxygen
- Serum MitoQ Level
- Needle Biopsy
- Record updated
- 24 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with peripheral artery disease who get leg pain when walking (claudication). It tests whether MitoQ taken for six months helps them walk better.
- Age
- 21 years and older
- Sex
- All sexes can join
- Disease stage
- Long-lasting leg pain when walking that limits exercise, seen by a vascular surgeon during a walking test. Blocked leg arteries shown by ankle/brachial index tests or artery imaging.
- Earlier treatment
- Blood pressure, cholesterol and diabetes treatments must have been stable for 6 weeks.
Main reasons for not taking part
- Pain at rest or tissue loss from the artery disease (Fontaine stage III and IV)
- A sudden loss of blood flow to the leg
- Walking mainly limited by other problems, such as joint, muscle or nerve problems
- Walking mainly limited by heart or lung disease
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- a positive history of chronic claudication
- exercise-limiting claudication established by history and direct observation during a screening walking test administered by the evaluating vascular surgeon
- documented lower extremity arterial occlusive disease based on ankle/brachial index measurements and/or arterial imaging
- stable blood pressure, lipid and diabetes regimens and risk factor control for 6 weeks
Who cannot take part
- walking capacity significantly and primarily limited by conditions other than claudication including leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology
- rest pain or tissue loss due to PAD (Fontaine stage III and IV)
- acute lower extremity ischemic event
Where in United States
- VA Medical CenterOmaha, United StatesContact: Holly DeSpiegelaereTaking people
About the trial
What the trial wants to find out
In our research, we are delving into whether taking MitoQ for six months can improve the symptoms and function of people diagnosed with peripheral artery disease, especially those who suffer from leg pain while walking, known as intermittent claudication. We will be checking if MitoQ helps people with claudication walk better, be more active every day, feel better about their lives, and if it enhances the health of their leg muscles.
The 2 groups in the trial
- MitoQExisting treatment, for comparison
Participants will be placed on a 24-week regimen of oral dosing with MitoQ. The patients will take two 20 mg caps of MitoQ on empty stomach, each morning
Treatment: Walking assessment, QOL Survey, Ankle pressure at rest and after stress, Muscle Oxygen, Serum MitoQ Level, and Needle Biopsy
- PlaceboPlacebo, for comparison
The patients will take two identical caps of matched placebo on empty stomach, each morning
Treatment: Walking assessment, QOL Survey, Ankle pressure at rest and after stress, Muscle Oxygen, Serum MitoQ Level, and Needle Biopsy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
- Plain-language title
- MitoQ for leg pain when walking caused by peripheral artery diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 24 February 2026